Prof. Dr. Alexander Schuhmacher

Forschung

• Pharma R&D models
• R&D efficiency
• Open innovation
• Artificial intelligence in pharma R&D

Vita

Akademische Ausbildung

• 2011-2012: Executive School of Management, Technology and Law, Universität St. Gallen (CH)
  Executive MBA in General Management
• 1999-2001: Universität Witten-Herdecke
  Master of Science in Pharmaceutical Medicine
• 1998-2001: Universität Konstanz
  Kooperatives Doktorandenprogramm und Promotion zum Dr. rer. nat.
• 1992-1997: Universität Konstanz
  Studium der Biologie, Abschluss: Dipl. Biol.

Beruflicher Werdegang

• Seit 09/2021: Professor für Life Science Management
  Technische Hochschule Ingolstadt
• 2012 – 2021: Professor für Technologie- und Innovationsmanagement
  Hochschule Reutlingen
• 2011-2012: Geschäftsführer
  Waldsee Golf Management GmbH
• 2007 – 2010: Hauptabteilungsleiter, Strategic Planning & Business Support
  Nycomed
• 2004 – 2007: Abteilungsleiter, F&E Portfolio-Management
  ALTANA Pharma AG
• 2001 – 2004: Patentexperte
  ALTANA Pharma AG
• 1998 – 2000: Wissenschaftlicher Mitarbeiter/Doktorand, Abteilung Biochemie
  Byk Gulden Lomberg

Veröffentlichungen

Eine Auswahl neuerer Publikationen (Fachartikel, peer-reviewed)

Schuhmacher A, Brieke C, Gassmann O, Hinder M, Hartl D. (2021) Systematic risk identification and assessment using a new risk map in pharmaceutical R&D. Drug Discov Today. 3: S1359-6446(21)00287-7. doi: 10.1016/j.drudis.2021.06.015.

Hartl D, de Luca V, Kostikova A, Laramie J, Kennedy S, Ferrero E, Siegel R, Fink M, Ahmed S, Millholland J, Schuhmacher A, Hinder M, Piali L, Roth A. (2021) Translational precision medicine: an industry perspective. J Transl Med. 19(1): 245. doi: 10.1186/s12967-021-02910-6.

Schuhmacher A, Gatto A, Kuss M, Gassmann O, Hinder M. Big Techs and startups in pharmaceutical R&D - A 2020 perspective on artificial intelligence (2021) Drug Discov Today 7: S1359-6446(21)00215-4. doi: 10.1016/j.drudis.2021.04.028.

Schuhmacher A, Wilisch L, Kuss M, Kandelbauer A, Hinder M, Gassmann O. (2021) R&D efficiency of leading pharmaceutical companies - A 20-year analysis. Drug Discov Today 26 (8):1784-1789. doi: 10.1016/j.drudis.2021.05.005.

Schuhmacher A, Gassmann O, Hinder M, Kuss M. (2021) The present and future of project management in pharmaceutical R&D. Drug Discov Today. 26(1): 1-4. doi: 10.1016/j.drudis.2020.07.020.

Schuhmacher A, Gatto A, Hinder M, Kuss M, Gassmann O. (2020) The upside of being a digital pharma player. Drug Discov Today. 25(9): 1569-1574. doi: 10.1016/j.drudis.2020.06.002.

Schuhmacher A, Kuss M. (2020) The impact of crowdsourcing in modern drug discovery. Expert Opin Drug Discov. 15(8): 865-867. doi: 10.1080/17460441.2020.1751116.

Schuhmacher, A., Gassmann, O., Kuss, M., Hinder, M. (2019) The Art of Virtualizing Pharma R&D. Drug Discovery Today 24: 2105-2107

Behbehani M., Glen A., Taylor C.S., Schuhmacher A., Claeyssens F., Haycock J.W. (2018) Pre-clinical evaluation of advanced nerve guide conduits using a novel 3D in vitro testing model. International Journal of Bioprinting 4: 123. http://dx.doi.org/10.18063/IJB.v4i1.123

Schuhmacher A., Gassmann O., McCracken N., Hinder M. (2018) Open innovation and external sources of innovation. An opportunity to fuel the R&D pipeline and enhance decision making? Journal of Translational Medicine. DOI: 10.1186/s12976-018-1499-2

Schuhmacher A, Gassmann O, Hinder M (2016) Changing R&D models in research‑based pharmaceutical companies. Journal of Translational Medicine, Vol. 14, pp. 105-115